PubMed Health⌕ Search

Biomedical subjects

Tuncalp Demir

Publications and source records attributed to Tuncalp Demir.

6 recordsLinked to original sources
PubMed2006

Pulmonary function in multiple sclerosis without any respiratory complaints.

OBJECTIVES: Pulmonary complications in severe multiple sclerosis (MS) are often seen secondary to respiratory muscle dysfunction. The development of respiratory muscle dysfunction and its association with disability during the course of MS is unknown. In our study, we investigated the predictive value of respiratory muscle functions and the change in forced vital capacity (Delta forced vital capacity [FVC]; FVC upright-FVC supine) to detect deterioration of respiratory muscle functions in the early phase of MS. PATIENTS AND METHODS: Twenty-one MS patients with a median age of 34.5+/-9.45 years were enrolled. Fourteen cases were relapsing-remitting, six were secondary progressive, one was primary progressive type. The mean duration of disease was 10.76+/-6.6 years. Seventeen healthy subjects with a median age of 40.7+/-7.6 years were chosen as a control group. Smoking habit was similar in both groups. Pulmonary function tests (PFT), lung volumes, diffusion, respiratory muscle function ( P(Imax) , P(Emax)), mouth occlusion pressure, and indirect sign of respiratory center function (P(0.1)) tests were performed. PFT were repeated in supine and upright positions. RESULTS: Our results in the MS group and the control group, respectively, were: diffusion (DL(CO): 18.8+/-4.2 vs. 26.4+/-7.3 mL/mmHg/min), P(I(max) (82.1+/-26.3 vs. 109.1+/-23.3 cm H(2)O), P(E(max) (119.2+/-42 vs. 171.8+/-50.2 cm H(2)O), P(0.1) (2.6+/-0.7 vs. 4.2+/-0.7). All parameters were lower in the MS group compared with the control group (p<0.05). In the MS group, FVC values in the upright position were higher than FVC values in the supine position. The difference in FVC values in MS patients between the upright and supine positions (Delta FVC) was also found to be significantly higher than in the control group (Delta FVC 262.3+/-247.6 (MS), 98.8+/-179.1 mL (CONTROL)) (p<0.01). CONCLUSION: Our results indicate the presence of pulmonary dysfunction in MS even in the absence of any respiratory symptoms.

Adult↗
PubMed2006

Plasma paraoxonase activities, lipoprotein oxidation, and trace element interaction in asthmatic patients.

Paraoxonase (PON1) protects low and high-density lipoproteins (LDL and HDL) against oxidation induced by reactive oxygen species formation facilitated by iron (Fe) and copper (Cu) ions. Plasma PON1, arylesterase, oxidized LDL (Ox-LDL), Cu, Fe, thiobarbituric acid-reactive substances (TBARS), lipid, lipoprotein, and apolipoprotein profile in bronchial asthma were determined and the relations among these parameters in different steps of asthma were interpreted. A total of 58 individuals, 30 asthmatics and 28 controls, were included into the scope of this study. Plasma PON1, arylesterase, and TBARS levels were measured spectrophotometrically. Determination of plasma oxidized LDL, Cu, and Fe levels were performed by enzyme-linked immunosorbent assay, atomic absorption spectrophotometry, and the automated TPTZ method, respectively. Apo-A-1 and Apo-B levels were determined immunoturbidometrically. Plasma total cholesterol, triglyceride, and HDL cholesterol levels were enzymatically determined. Plasma LDL levels were estimated using the Fridewald formula. The average plasma PON1 and arylesterase activities in the group of patients were lower than those of the individuals in the control group, but there was no statistically significant difference found between them (p > 0.05). No significant difference was found in plasma Apo-A-1, Apo-B, total cholesterol, triglyceride, HDL, and LDL concentrations between the control and patient groups (p > 0.05). Plasma oxidized LDL (p < 0.05), Cu (p < 0.01), Fe (p < 0.01), and TBARS (p < 0.001) levels in patients with asthma were found to be significantly higher than for the control group. Increases in Cu, Fe, lipid peroxidation, and oxidized LDL levels supported by relative decreases in PON1 activities observed in asthmatic patients might be introduced as the striking findings as well as the possible potential indicators of this airway disease, the prevalence of which has increased dramatically over recent decades.

Adult↗
PubMed2005

The role of FEV6 in the detection of airway obstruction.

OBJECTIVES: There are recent reports regarding the use of forced expiratory volume in 6 s (FEV6) in place of forced expiratory vital capacity (FVC) in the detection of airway obstruction. We aimed to investigate the role of FEV6 in comparison with FVC in the evaluation of airway obstruction. METHODS: The pulmonary function tests (PFT) results of all 5114 patients, who had been tested in the pulmonary function laboratory between 1998 and 2003, were retrospectively analyzed to investigate the relationship between FEV6 and FVC. RESULTS: We have found a mean difference of 95.35+/-121.7 (min=0, max=1050) ml (3.37%) when FVC and FEV6 values (FVC-FEV6) of all cases were compared. This difference was found to be higher (180 ml, 7.3%) in patients with airway obstruction. When FEV1/FVC is taken as the gold standard, FEV1/FEV6 had negative predictive value of 92.24% and a sensitivity of 86.09% in the detection of airway obstruction. CONCLUSIONS: Although it is easier to use FEV6 in place of FVC, relatively low sensitivity in that setting may result in the underestimation of airway obstruction. This drawback should be kept in mind when FEV6 is utilized to detect airway obstruction.

Adult↗
PubMed2004

The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients.

Mild persistent asthma is most effectively controlled with inhaled corticosteroids. Leukotriene receptor antagonists have complementary effects to corticosteroids on inflammation control. The additional effect of a leukotriene receptor antagonist, zafirlukast, was investigated in stable asthma patients under control with inhaled budesonide. We conducted a randomised, double-blind, placebo-controlled, single center trial to investigate the effects of add-on zafirlukast treatment to budesonide, on symptom score, pulmonary function, bronchial responsiveness, and serum levels of eosinophilic cationic protein (ECP) and antioxidant capacity in stable asthmatic patients under control with inhaled budesonide. The present study included 21 mild or moderate asthmatic patients (8 males and 13 females), who were stable at least for 6 weeks with inhaled budesonide (400 microg/day). Serum total antioxidant capacity (TAC) and ECP levels were measured, and symptom scoring, spirometry, and bronchial provocation with methacholine were performed. Then, the patients were randomised to use either placebo or oral zafirlukast (40 mg/day) in addition to budesonide for 6 weeks. At the 6th week, symptom scoring, spirometry, and bronchial provocation tests were repeated and serum TAC and ECP levels were measured again. After add-on zafirlukast treatment to budesonide, forced expiratory volume in 1 second (FEV(1)), TAC and ECP values did not change significantly (p > 0.05) but bronchial hyperresponsiveness and symptom score decreased significantly (p = 0.022) compared to baseline. Thus, in stable asthmatic patients, add-on zafirlukast treatment to budesonide improves symptoms and decreases bronchial hyperresponsiveness.

Adolescent↗
PubMedDate not supplied

Retrospective evaluation of patient compliance in continuous oxygen therapy.

BACKGROUND: Prescription of continuous oxygen therapy (COT) for correct indications, adequate education of the patients, and a regular and sufficient oxygen intake are essential. OBJECTIVE: To evaluate the indications of COT prescriptions in six different centers around Istanbul and patient compliance. METHODS: The initial data of the cases were taken from hospital records and throughout the study personal visits were done as well as arterial blood gas (ABG) analyses. RESULTS: 86 patients out of 110 (78.1%) were found to be eligible candidates for COT. Daily duration of therapy was more than 15 h in 55 (43.3%) and more than 12 h in 14 (11%) of the cases. During therapy, mean PaO(2) values have increased from 52.1 +/- 11 to 58.6 +/- 12 mm Hg (p < 0.001), while mean PaCO(2) values have decreased from 50.16 +/- 9.6 to 48.02 +/- 9 mm Hg (p < 0.05). 98 of the cases (77.1%) stated that they had benefited from the therapy. CONCLUSIONS: We conclude that COT is an effective treatment modality, but patient compliance remains a problem.

Adult↗